The uncomfortable question lingers. In those nine years, how many died prematurely or endured avoidable disease progression because subsidised access was not available? If ministerial intervention was critical to this outcome, why did the system require it again?
The nine-year wait should raise some important but uncomfortable questions - can we be better?
March 1, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Moderna expands support for early career Australian mRNA researchers
May 7, 2026 - - Latest News -
The review is formally over. Why is it restarting?
May 7, 2026 - - Latest News -
AI screening tool gives pathologists 'super' vision to detect hidden cancer
May 7, 2026 - - Latest News -
Australian company celebrated in centenary project on royal and parliamentary leadership
May 6, 2026 - - Latest News -
La Trobe launches REACH program to fight antimicrobial resistance
May 6, 2026 - - Latest News -
If the imperative is international comparison, why limit it to these definitions?
May 5, 2026 - - Latest News -
Therapy funded three years after the 'clunky' and 'preventable deaths' admission
May 5, 2026 - - Latest News
